Recent Patents on Drug Delivery & Formulation

Publisher: Bentham Science Publishers

Description

Recent Patents on Drug Delivery & Formulation publishes review articles by experts on recent patents on drug delivery and formulation. A selection of important and recent annotated patents on drug delivery and formulation is also included in the journal. The journal is essential reading for all researchers involved in the fields of drug delivery and formulation.

  • Impact factor
    0.00
  • 5-year impact
    0.00
  • Cited half-life
    0.00
  • Immediacy index
    0.00
  • Eigenfactor
    0.00
  • Article influence
    0.00
  • Website
    Recent Patents on Drug Delivery and Formulation website
  • Other titles
    Recent patents on drug delivery and formulation, Drug delivery & formulation, Drug delivery and formulation
  • ISSN
    1872-2113
  • OCLC
    163586653
  • Document type
    Journal / Magazine / Newspaper

Publisher details

Bentham Science Publishers

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months (unless federal, government, funding agencies or local policy mandates for the author's institute a different policy on self-archiving)
  • Conditions
    • On authors personal or authors institutions server
    • Published source must be acknowledged
    • Must link to journal home page
    • Publisher's version/PDF cannot be used
    • Articles in all journals can be made Open Access on payment of additional charge
  • Classification
    ‚Äč yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The much interest in the preparation (SEDDS) is to be a unique feasible approach to overcome low oral bioavailability problem and it is associated with the hydrophobic drugs due to their unparalleled potential as a drug delivery with the broad range of application. The estimated 40% of active pharmaceuticals are poorly water soluble. Now recently, formulation containing oral SEDDS has received much interest as a way to solve problems related to oral bioavailability, intra and inter-subject variability, lack of dose proportionality of hydrophobic drugs and now today it is the first way to investigated in the development of any kinds innovative dosage forms. Many important in-vitro characteristics such as surfactant concentration, oil/surfactant ratio, emulsion polarity, droplet size and zeta potential plays an important role in oral absorption of drug from SEEDS. It can be orally administered in the form of SGC or HGC and also enhance bioavailability of drugs to increase solubility and minimizes the gastric irritation. After administering the drug remains entrapped in the oily droplets (inside the droplet or in the surfactant`s film at the interface) of the emulsion that is being formed in the GIT upon self-emulsification process. It is also a bit problematic to say that the drug is being released from SMEDDS, it is more correct to say that it diffuses out of oily droplets into the GIT media and actually the equilibrium is formed between the drug dissolved in oily droplets and the outer dispersed media (e.g. GIT fluids). Many of the application and preparation method of SEDDS are reported by research articles and patents in different countries. We present an exhaustive and updated account of numerous literature reports and more than 150 patents published on SEDDS on recent period. We focused; this current patent review is useful in knowledge of SEDDS for its preparations and patents in different country with emphasis on their formulation, characterization and systematic optimization strategies, thus paving the way for accelerated progress into the SEDDS application in pharmaceutical research as well as patents on SEDDS methods.
    Recent Patents on Drug Delivery & Formulation 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eye inflammation, if untreated at right time poses the risk of vision loss. Several categories of drugs are available in the global market, but corticosteroids are still used for the treatment of ocular inflammation including anterior/posterior uveitis, age related macular degeneration (AMD) and post cataract surgery inflammation. Although corticosteroids have well-documented side effects as compared to non steroidal anti-inflammatory drugs (NSAIDs), but they are still regarded as better anti-inflammatory agents for treating ocular inflammations. The prime concern with conventional formulations such as (ophthalmic solutions, suspensions, ointments) is low drug bioavailability due to precorneal barrier of the eye, tear turnover and rapid drainage of drug via nasolacrimal drainage and drug induced systemic toxicity. To overcome these limitations, various novel formulations of corticosteroids have been explored. These include nanoparticles, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), nanomicelles, in-situ gels, iontophoresis, liposomes, nanoemulsions, microemulsions and ocular implants for the effective ophthalmic delivery of the corticosteroids. Topical nanocarriers have also been demonstrated to be promising vectors with potential application in the ophthalmic therapeutics. This review summarizes the clinical findings and patents on various corticosteroids as ocular pharmacotherapeutics.
    Recent Patents on Drug Delivery & Formulation 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present critical review is related with the self modified patch based drug delivery system for controlled (trans)dermal drug delivery. The composition itself modified into the patch and adheres when comes onto the skin contact and acts as a rate-controlling matrix layer (patch). The self adhesiveness property of the formulation itself is enough to hold the patch in place on the skin for the encouraged duration of treatment while allowing the patch to be promptly backed away without any skin irritation and formulation residue. This patent review is useful in knowledge of self modified patch associated drug delivery for controlled topical or transdermal delivery of pharmaceutical and cosmetic agents.
    Recent Patents on Drug Delivery & Formulation 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral administration of Insulin, however, is extremely difficult due to their extremely low bioavailability. Development of oral Insulin formulations requires overcoming obstacles, such as low permeability of large molecules, lack of lipophilicity, and inactivation or rapid enzymatic degradation in the gastrointestinal (GI) tract. The successful oral delivery of Insulin involves overcoming the barrier of enzymatic degradation, achieving epithelial permeability, and conserving the bioactivity of the drug during formulation processing. Strategies proposed to maximize oral Insulin bioavailability in Insulin delivery systems, to overcome barriers, and to develop safe and effective therapies, by using specific excipients, such as absorption enhancers, enzyme inhibitors, and mucoadhesive polymers, and using composition allowing protection of Insulin from the harsh environment in the GI tract. The present review includes study of patents on oral Insulin delivery. All the patents in the present review are arranged and interconnected in such a way to improve viewer's knowledge at glance. The comparative comments and discussions on the entitled topic make it easier to understand.
    Recent Patents on Drug Delivery & Formulation 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been documented that telomere-associated cellular senescence may contribute to certain age-related disorders, including an increase in cancer incidence, wrinkling and diminished skin elasticity, atherosclerosis, osteoporosis, weight loss, age-related cataract, glaucoma and others. Shorter telomere length in leukocytes was associated cross-sectionally with cardiovascular disorders and its risk factors, including pulse pressure and vascular aging, obesity, vascular dementia, diabetes, coronary artery disease, myocardial infarction (although not in all studies), cellular turnover and exposure to oxidative and inflammatory damage in chronic obstructive pulmonary disease . It has been proposed that telomere length may not be a strong biomarker of survival in older individuals, but it may be an informative biomarker of healthy aging. The data reveal that telomere dynamics and changes in telomerase activity are consistent elements of cellular alterations associated with changes in proliferative state and in this article these processes are consequently considered as the new therapeutic drug targets for physiological control with advanced drug delivery and nutritional formulations. In particular, the presence of highly specific correlations and early causal relationships between telomere loss in the absence of telomerase activity and replicative senescence or crisis, and from the other side, telomerase reactivation and cell immortality, point to a new and important treatment strategies or the therapeutic manipulation during treatment of age related disorders and cancer. Once better controls and therapeutic treatments for aging and age-related disorders are achieved, cellular rejuvenation by manipulating telomeres and enzyme telomerase activity may reduce some of the physiological declines that accompany aging. In this work we raise and support a therapeutic concept of using non-hydrolized forms of naturally occurring imidazole-dipeptide based compounds carnosine and carcinine, making it clinically possible that slowing down the rate of telomere shortening could slow down the human aging process in specific tissues where proliferative senescence is known to occur with the demonstrated evidence of telomere shortening appeared to be a hallmark of oxidative stress and disease. The preliminary longitudinal studies of elderly individuals suggest that longer telomeres are associated with better survival and an advanced oral nutritional support with non-hydrolized carnosine (or carcinine and patented compositions thereof) is a useful therapeutic tool of a critical telomere length maintenance that may fundamentally be applied in the treatment of age-related sight-threatenting eye disorders, prolong life expectancy, increase survival and chronological age of an organism in health control, smoking behavior and disease.
    Recent Patents on Drug Delivery & Formulation 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin was discovered over 90 years ago. From then till now oral insulin is still a challenging and elusive goal. However huge efforts are being done worldwide for developing noninvasive drug delivery systems, mainly via oral route as it is the most widely accepted means of administration. The main barriers faced in oral protein delivery are the enzymatic degradation and poor permeability across the intestinal wall. All the approaches for oral insulin are on how to overcome these barriers. To overcome the gastro-intestinal barriers various types of formulations such as insulin conjugates, permeation enhancers, micro/nanoparticles, liposomes etc. are investigated. In the recent years lot of advances have taken place in understanding of the oral peptide delivery systems. In this review the recent patents on oral insulin is focused. Emphasis is on the technologies based on permeation enhancers and nanoparticle based carrier systems.
    Recent Patents on Drug Delivery & Formulation 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: High lipophilicity and high lattice energy of drugs, which result in poor solubility are major real challenges in the pharmaceutical industry for the successful development and commercialization of suitable dosage forms. Therefore various formulation strategies like complexation, lipid based systems, micronization, nanonization, co-crystals, solid dispersions, solubilization etc. have been investigated to resolve the problems associated with solubility related oral bioavailability of poorly water soluble drugs. This article focuses on solid dispersions which is used as one of the formulation strategies to improve the solubility and bioavailability of BCS class II drugs. The present review discusses the fundamentals of solid dispersions, their formulation techniques including various carriers used, their applications, limitations as well as provide an insight into the various alternative approaches to overcome problems associated with solid dispersions. This review also discusses some important aspects of solid dispersion like phase transition, importance of Tg for solid dispersion, controlled release formulations, IVIVC, and the prospect of innovative solid dispersions. Furthermore, the different patents highlighting the applications of solid dispersions have also been comprehensively discussed in the present review.
    Recent Patents on Drug Delivery & Formulation 08/2011; 5(3):244-264.
  • Recent Patents on Drug Delivery & Formulation 01/2010; 4(2):1-16.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In an effort to improve the drug solubility, stability and/or ocular bioavailability of ophthalmic formulations, various approaches have been explored in the recent past. Additionally, different formulations have been investigated in order to seek those preservative systems that are more tolerable to the ocular tissue. Over the past ten years, inventions in ophthalmic formulations directed toward front-of-eye instillations have concentrated in the areas of new excipients' applications, novel and combined use of conventional excipients, and developments of novel dosage forms. Among these areas, applications of polymeric excipients, cyclodextrins and stabilized chloride dioxide (SCD) have been the most actively studied fields. In addition, oil-in-water (O/W) emulsions have been becoming more popular as an ophthalmic dosage form due to the potentials in increasing drug solubility, stabilizing active pharmaceutical ingredients (APIs), improving ocular tolerance, and providing palliative effects. Some of these innovations from the past decade have the capability of leading to new commercial products. This patent review has a useful knowledge in the advancement for treating various ophthalmic diseases.
    Recent Patents on Drug Delivery & Formulation 12/2009; 4(1):49-57.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the recent years, there has been a growing interest in the development of nanoparticles based targeting agents for the tumor diagnostics and therapeutics. This is because of their potential to detect the tumor and treat the diseased tissue at the cellular and molecular level. In this respect nanoscale magnetic materials have shown a very promising therapeutic concept and offer a new perspective for the diagnostic and target drug delivery approach. The magnetic nanocarriers have the ability to accumulate at any desired pharmacological site just by the guidance of external magnetic field. But, the interactions of these magnetic nanocarriers with the biological environment are rare and depend largely upon their surface chemistry and size. To increase the interactions and achieve the desired pharmaceutically acceptable delivery system, the surface of magnetic nanocarriers is modified in various ways by coating with organic polymers and inorganic metals or oxides. On the basis of surface characteristics, a number of effective magnetically driven therapies have been proposed by many researchers and protected through patents time to time.
    Recent Patents on Drug Delivery & Formulation 03/2009;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, there is a greater global interest in non synthetic, natural medicines derived from plant sources due to better tolerance and minimum adverse drug reactions as compared to synthetic medicines. Herbal products are also commonly used by the patients with certain chronic medical conditions, including breast cancer, liver disease, human immunodeficiency, asthma and rheumatological disorders. WHO estimates that about three-quarters of the world's population currently uses herbs and other forms of traditional medicines for the treatment of various diseases. The herbs are formulated in different modern dosage forms, such as Tablets, Capsules, Topical cream, Gel, Ointment and even some novel drug delivery forms, like extended release, sustained release, and microencapsules dosage forms. Patenting of herbal formulations has increased over the past few years and scientific evidence of therapeutic activity has been reported by performing various in vitro and in vivo experiments. This manuscript deals with various patented herbal formulations with their therapeutic application against various disases.
    Recent Patents on Drug Delivery & Formulation 01/2009;

Related Journals